Autoantibodies as Diagnostic Biomarkers for Lung Cancer

Authors

  • Heera Batool Center for Advanced Studies in Vaccinology and Biotechnology, (CASVAB), UoB, Quetta Author
  • Masooma Center for Advanced Studies in Vaccinology and Biotechnology Author
  • Salma Khalid Center for Advanced Studies in Vaccinology and Biotechnology, (CASVAB), UoB, Quetta Author
  • Bilal Ahmad Mian Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan Author
  • Irfan Ullah Directorate of Cereal Crops, Agriculture Research Institute, Quetta, Pakistan Author

DOI:

https://doi.org/10.31580/pjmls.v5i3.2738

Keywords:

Antibodies, Autoantibodies, Diagnostic biomarkers, Lung cancer, P53

Abstract

Lung cancer is one of the leading causes of death worldwide, with two main types of the disease - non-small cell lung malignancies and small cell lung cancer - accounting for approximately 85% and 15% of mortalities respectively. Like other diseases and infections, lung cancer can also be diagnosed by tumor markers that are produced by Lung cancer patients. Antibodies from five classes of antibodies are IgG, IgM, IgA, IgD, and IgE are produced against their own antigens known as autoantibodies, have their role in stopping or minimizing cancer, and play a vital role in diagnostic analysis of lung cancer. To diagnose lung cancer, a panel of six antibodies p53, CAGE, GBU4–5, NY-ESO-1, Annexin 1, and SOX2 has been studied to monitor lung cancer with a sensitivity of 38% and a specificity of 88 percent. Patients with lung cancer can produce p53 antibodies, an altered form of tumor suppressor known as Tp53. Other antibodies like NY-ESO 1, Annexin A1 and SOX2 can also be used as diagnostic biomarkers for the detection of lung cancer. In this review, we study all possible antitumor or Autoantibodies of lung cancer and their use in earlier detection of a lung cancer diagnosis.

Author Biographies

  • Masooma, Center for Advanced Studies in Vaccinology and Biotechnology
    Lung cancer is one of the leading causes of death worldwide, with two main types of the disease - non-small cell lung malignancies and small cell lung cancer - accounting for approximately 85% and 15% of mortalities respectively. Like other diseases and infections, lung cancer can also be diagnosed by tumor markers that are produced by Lung cancer patients. Antibodies from five classes of antibodies are IgG, IgM, IgA, IgD, and IgE are produced against their own antigens known as autoantibodies, have their role in stopping or minimizing cancer, and play a vital role in diagnostic analysis of lung cancer. To diagnose lung cancer, a panel of six antibodies p53, CAGE, GBU4–5, NY-ESO-1, Annexin 1, and SOX2 has been studied to monitor lung cancer with a sensitivity of 38% and a specificity of 88 percent. Patients with lung cancer can produce p53 antibodies, an altered form of tumor suppressor known as Tp53. Other antibodies like NY-ESO 1, Annexin A1 and SOX2 can also be used as diagnostic biomarkers for the detection of lung cancer. In this review, we study all possible antitumor or Autoantibodies of lung cancer and their use in earlier detection of a lung cancer diagnosis.
  • Bilal Ahmad Mian, Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan
    Lung cancer is one of the leading causes of death worldwide, with two main types of the disease - non-small cell lung malignancies and small cell lung cancer - accounting for approximately 85% and 15% of mortalities respectively. Like other diseases and infections, lung cancer can also be diagnosed by tumor markers that are produced by Lung cancer patients. Antibodies from five classes of antibodies are IgG, IgM, IgA, IgD, and IgE are produced against their own antigens known as autoantibodies, have their role in stopping or minimizing cancer, and play a vital role in diagnostic analysis of lung cancer. To diagnose lung cancer, a panel of six antibodies p53, CAGE, GBU4–5, NY-ESO-1, Annexin 1, and SOX2 has been studied to monitor lung cancer with a sensitivity of 38% and a specificity of 88 percent. Patients with lung cancer can produce p53 antibodies, an altered form of tumor suppressor known as Tp53. Other antibodies like NY-ESO 1, Annexin A1 and SOX2 can also be used as diagnostic biomarkers for the detection of lung cancer. In this review, we study all possible antitumor or Autoantibodies of lung cancer and their use in earlier detection of a lung cancer diagnosis.
  • Irfan Ullah, Directorate of Cereal Crops, Agriculture Research Institute, Quetta, Pakistan
    Lung cancer is one of the leading causes of death worldwide, with two main types of the disease - non-small cell lung malignancies and small cell lung cancer - accounting for approximately 85% and 15% of mortalities respectively. Like other diseases and infections, lung cancer can also be diagnosed by tumor markers that are produced by Lung cancer patients. Antibodies from five classes of antibodies are IgG, IgM, IgA, IgD, and IgE are produced against their own antigens known as autoantibodies, have their role in stopping or minimizing cancer, and play a vital role in diagnostic analysis of lung cancer. To diagnose lung cancer, a panel of six antibodies p53, CAGE, GBU4–5, NY-ESO-1, Annexin 1, and SOX2 has been studied to monitor lung cancer with a sensitivity of 38% and a specificity of 88 percent. Patients with lung cancer can produce p53 antibodies, an altered form of tumor suppressor known as Tp53. Other antibodies like NY-ESO 1, Annexin A1 and SOX2 can also be used as diagnostic biomarkers for the detection of lung cancer. In this review, we study all possible antitumor or Autoantibodies of lung cancer and their use in earlier detection of a lung cancer diagnosis.

References

Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011;22(2):383–9.

Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM. Immunobiomarkers in small cell lung cancer: Potential early cancer signals. Clin Cancer Res. 2011;17(6):1474–80.

Li N, Holden VK, Deepak J, Todd NW, Jiang F. Autoantibodies against tumor-associated antigens in sputum as biomarkers for lung cancer. Transl Oncol. 2021;14(2):100991.

Lukeman JM. What Is Lung Cancer? Perspect Lung Cancer. 2015;30–40.

November A. Lung cancer Worldwide Lung Cancer in Arab Populations. 2011;(Globocan 2008).

Jiang D, Wang Y, Liu M, Si Q, Wang T, Pei. A panel of autoantibodies against tumor-associated antigens in the early immunodiagnosis of lung cancer. Immunobiology. 2020;225(1).

Mutneja M, Mohan C, Long KD, Das C. An Introduction to Antibodies and Their Applications. EMD Millipore. 2014;2015:100.

Wootla B, Denic A, Rodriguez M. Polyclonal and monoclonal antibodies in clinic. Vol. 1060, Methods in Molecular Biology. 2014. 79–110 p.

Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci [Internet]. 2020;109(1):74–103.

Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4(OCT).

Weis-Garcia F, Carnahan RH. Characterizing Antibodies. Cold Spring Harb Protoc. 2017;2017(11):857–69.

Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals. 2008;36(6):363–74.

Ali Khan W. Introductory Chapter: Autoantibodies and Their Types. Autoantibodies and Cytokines. 2019;3–12.

Elkon K, Casali P. Nature, and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491–8.

Lacroix-Desmazes S, Kaveri S V., Mouthon L, Ayouba A, Malanchère E, Coutinho. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998;216(1–2):117–37.

Haynes BF, Saunders KO, Kelsoe G, Mascola JR, Nabel GJ. The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies. Second Edi. Molecular Biology of B Cells: Second Edition. Elsevier Ltd; 2015. 441–461 p.

Uyar NY. Structure, Physiology, and Functions of Autoantibodies. InAutoantibodies and Cytokines 2018 Nov 5. IntechOpen.

de Jonge H, Iamele L, Maggi M, Pessino G, Scotti C. Anti-cancer auto-antibodies: Roles, applications and open issues. Cancers (Basel). 2021;13(4):1–30.

Bendtzen K, Hansen MB, Ross C, Svenson M. Detection of autoantibodies to cytokines. Appl Biochem Biotechnol - Part B Mol Biotechnol. 2000;14(3):251–61.

Qin J, Zeng N, Yang T, Wan C, Chen L, Shen Y. Diagnostic value of autoantibodies in lung cancer: A systematic review and meta-analysis. Cell Physiol Biochem. 2019;51(6):2631–46.

Yang B, Li X, Ren T, Yin Y. Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review. Cell Death Discov. 2019;5(1).

Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci Ö. Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure. Thorax. 2008;63(3):228–33.

Mattioni M, Soddu S, Prodosmo A, Visca P, Conti S, Alessandrini G. Prognostic role of serum p53 antibodies in lung cancer. BMC Cancer. 2015;15(1):1–11.

Soussi T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 2000;60(7):1777–88.

Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of the breast: Correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005;93(2):111–5.

Lubin R, Zalcman G, Bouchet L, Tr É Daniel J, Legros Y, Cazals D. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1(7):701–2.

Zhang J, Xu Z, Yu L, Chen M, Li K. Assessment of the potential diagnostic value of serum p53 antibody for cancer: A meta-analysis. PLoS One. 2014;9(6).

Park Y, Kim Y, Lee JH, Lee EY, Kim HS. The usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Arch Pathol Lab Med. 2011;135(12):1570–5.

Yu DH, Li JH, Wang YC, Xu JG, Pan PT, Wang L. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcinoembryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin Chim Acta [Internet]. 2011;412(11–12):930–5.

Kumar S, Mohan A, Guleria R. Prognostic implications of circulating anti-p53 antibodies in lung cancer - A review. Eur J Cancer Care (Engl). 2009;18(3):248–54.

Decock J. NY-ESO-1 Based Immunotherapy of Cancer : Current Perspectives. 2018;9(May).

Lim LHK, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J. 2007;21(4):968–75.

Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W. Elevated serum annexin A1 as a potential diagnostic marker for lung cancer: A retrospective case-control study. Am J Transl Res. 2014;6(5):558–69.

Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: Branching morphogenesis and epithelial cell differentiation. Dev Biol. 2008;317(1):296–309.

Wu Y, Du X, Xue C, Li D, Zheng Q, Li X. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer. Med Oncol. 2013;30(4).

Downloads

Published

2022-09-30

Issue

Vol. 5 No. 3 (2022): July-September

Section

Review Article

License

Copyright (c) 2023 Pak-Euro Journal of Medical and Life Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Autoantibodies as Diagnostic Biomarkers for Lung Cancer. (2022). Pak-Euro Journal of Medical and Life Sciences, 5(3), 555-556. https://doi.org/10.31580/pjmls.v5i3.2738

Similar Articles

11-20 of 87

You may also start an advanced similarity search for this article.